Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Hodge Website

James W. Hodge, Ph.D., MBA

Selected Publications

1)  Donahue RN, Duncan BB, Fry TJ, Jones B, Bachovchin WW, Kiritsy CP, Lai JH, Wu W, Zhao P, Liu Y, Tsang KY, Hodge JW.
A pan inhibitor of DASH family enzymes induces immunogenic modulation and sensitizes murine and human carcinoma cells to antigen-specific cytotoxic T lymphocyte killing: implications for combination therapy with cancer vaccines.
Vaccine. 2014.
2)  Wattenberg MM, Kwilas AR, Gameiro SR, Dicker AP, Hodge JW.
Expanding the use of monoclonal antibody therapy of cancer by using ionising radiation to upregulate antibody targets.
Br. J. Cancer. 110: 1472-80, 2014.
3)  Campbell CT, Gulley JL, Oyelaran O, Hodge JW, Schlom J, Gildersleeve JC.
Humoral response to a viral glycan correlates with survival on PROSTVAC-VF.
Proc. Natl. Acad. Sci. U.S.A. 2014.
4)  Gameiro SR, Jammeh ML, Wattenberg MM, Tsang KY, Ferrone S, Hodge JW.
Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing.
Oncotarget. 5: 403-16, 2014.
5)  Bernstein MB, Garnett CT, Zhang H, Velcich A, Wattenberg MM, Gameiro SR, Kalnicki S, Hodge JW, Guha C.
Radiation-Induced Modulation of Costimulatory and Coinhibitory T-Cell Signaling Molecules on Human Prostate Carcinoma Cells Promotes Productive Antitumor Immune Interactions.
Cancer Biother. Radiopharm. 2014.
6)  Ardiani A, Gameiro SR, Palena C, Hamilton DH, Kwilas A, King TH, Schlom J, Hodge JW.
Vaccine-Mediated Immunotherapy Directed against a Transcription Factor Driving the Metastatic Process.
Cancer Res. 2014.
7)  Huang J, Jochems C, Anderson AA, Talaie T, Jales A, Madan RA, Hodge JW, Tsang KY, Liewehr DJ, Steinberg SM, Gulley JL, Schlom J.
Soluble CD27-pool in humans may contribute to T-cell activation and tumor immunity.
J Immunol. 2013.
In Press. [Journal]
8)  Singh N, Hodge JW, Madan R, Gulley JL.
Shurin MR, Umansky V, Malyguine A, eds.
Combining vaccines with therapies that render tumor cells more susceptible to immune mediated killing. In: The Tumor Immunoenvironment.
Dordrecht: Springer Science+Business Media; 2013. p. 621-642 [Book Chapter]
9)  Hodge JW, Kwilas A, Ardiani A, Gameiro SR.
Attacking malignant cells that survive therapy: Exploiting immunogenic modulation.
Oncoimmunology. 2: e26937, 2013.
10)  Gameiro SR, Jammeh ML, Hodge JW.
Cancer vaccines targeting carcinoembryonic antigen: state-of-the-art and future promise.
Expert Rev Vaccines. 12: 617-29, 2013.
11)  Hodge JW, Garnett CT, Farsaci B, Palena C, Tsang K, Ferrone S, Gameiro SR.
Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death.
Int. J. Cancer. [Epub ahead of print], 2013.
12)  Ardiani A, Farsaci B, Rogers CJ, Protter A, Guo Z, King TH, Apelian D, Hodge JW.
Combination therapy with a second-generation androgen receptor antagonist and a metastasis vaccine improves survival in a spontaneous prostate cancer model.
Clin. Cancer Res. 19: 6205-18, 2013.
13)  Gameiro SR, Higgins JP, Dreher MR, Woods DL, Reddy G, Wood BJ, Guha C, Hodge JW.
Combination therapy with local radiofrequency ablation and systemic vaccine enhances antitumor immunity and mediates local and distal tumor regression.
PLoS ONE. 8: e70417, 2013.
14)  Hamilton DH, Litzinger MT, Jales A, Huang B, Fernando RI, Hodge JW, Ardiani A, Apelian D, Schlom J, Palena C.
Immunological targeting of tumor cells undergoing an epithelial-mesenchymal transition via a recombinant brachyury-yeast vaccine.
Oncotarget. 4: 1777-90, 2013.
15)  Bernstein MB, Ohri N, Hodge JW, Garg M, Bodner W, Kalnicki S, Dicker AP, Guha C.
Prostate-specific antigen bounce predicts for a favorable prognosis following brachytherapy: a meta-analysis.
J Contemp Brachytherapy. 5: 210-4, 2013.
16)  Campbell CT, Gulley JL, Oyelaran O, Hodge JW, Schlom J, Gildersleeve JC.
Serum Antibodies to Blood Group A Predict Survival on PROSTVAC-VF.
Clin. Cancer Res. 19: 1290-9, 2013.
17)  Huang J, Jochems C, Anderson AM, Talaie T, Jales A, Madan RA, Hodge JW, Tsang KY, Liewehr DJ, Steinberg SM, Gulley JL, Schlom J.
Soluble CD27-pool in humans may contribute to T cell activation and tumor immunity.
J. Immunol. 190: 6250-8, 2013.
18)  Huang B, Cohen JR, Fernando RI, Hamilton DH, Litzinger MT, Hodge JW, Palena C.
The embryonic transcription factor Brachyury blocks cell cycle progression and mediates tumor resistance to conventional antitumor therapies.
Cell Death Dis. 4: e682, 2013.
19)  Hodge JW, Sharp HJ, Gameiro SR.
Abscopal regression of antigen disparate tumors by antigen cascade after systemic tumor vaccination in combination with local tumor radiation.
Cancer Biother. Radiopharm. 27: 12-22, 2012.
20)  Heery CR, Hodge JW, Gulley JL.
Combining radiation and therapeutic cancer vaccines: a synergistic approach.
Breast Cancer Management. 1: 325-335, 2012.
21)  Gameiro SR, Caballero JA, Hodge JW.
Defining the molecular signature of chemotherapy-mediated lung tumor phenotype modulation and increased susceptibility to T-cell killing.
Cancer Biother. Radiopharm. 27: 23-35, 2012.
22)  Kwilas AR, Donahue RN, Bernstein MB, Hodge JW.
In the field: exploiting the untapped potential of immunogenic modulation by radiation in combination with immunotherapy for the treatment of cancer.
Front Oncol. 2: 104, 2012.
23)  Schlom J, Hodge JW.
Introduction: therapeutic cancer vaccines.
Semin. Oncol. 39: 243-4, 2012.
24)  Hodge JW, Ardiani A, Farsaci B, Kwilas AR, Gameiro SR.
The tipping point for combination therapy: cancer vaccines with radiation, chemotherapy, or targeted small molecule inhibitors.
Semin. Oncol. 39: 323-39, 2012.
25)  Farsaci B, Kwilas A, Hodge JW.
Bot A, Obrocea M, Marincola F, eds.
Design, development and translation of poxvirus-bassed vaccines for cancer (Chapter 5). In: Cancer Vaccines: From Research to Clinical Practice.
London: Informa Healthcare Books; 2011. p. 56-77 [Book Chapter]
26)  Schlom J, Hodge JW, Palena C, Greiner JW, Tsang KY, Farsaci B, Madan RA, Gulley JL.
Prendergast G, Jaffee E, eds.
Recombinant TRICOM-based therapeutic cancer vaccines: lessons learned. In: Cancer Immunotherapy.
Elsevier; . In Press. [Book Chapter]
27)  Boehm AL, Donahue R, Hodge JW.
Marshall J, eds.
The B7-1 costimulatory molecule. In: Encyclopedia of Cancer Therapeutic Targets.
Springer; . In Press. [Book Chapter]
28)  Schlom J, Palena C, Gulley JL, Greiner JW, Tsang KY, Madan RA, Hodge JW.
Lattime E, Gerson S, eds.
The use of T-cell costimulation to enhance the immunogenicity of tumors. In: Gene Therapy of Cancer: Translational Approaches from Preclinical Studies to Clinical Implementation, Third Edition.
Elsevier; . In Press. [Book Chapter]
29)  Farsaci B, Kim PS, Hodge JW, Palena C, Gulley JL, Schlom J.
Giaccone G, Soria J, eds.
Vaccine therapy and integration with other modalities. In: Targeted Therapies in Oncology, Second Edition.
CRC Press; . In Press. [Book Chapter]
30)  Gameiro SR, Jammeh M, Hodge JW.
Cancer vaccines targeting carcinoembryonic antigen (CEA): state of the art and future promise.
Expert Reviews in Vaccines. .
In Press. [Journal]
31)  Wattenberg MM, Ahmed F, Ahmed MM, Hodge JW.
Unlocking the combination: potentiation of radiation-induced antitumor responses with immunotherapy [review].
Radiation Research. .
In Press. [Journal]
32)  Farsaci B, Higgins JP, Hodge JW.
Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy.
Int J Cancer. [Epub ahead of print], 2011.
33)  Gameiro SR, Caballero JA, Higgins JP, Apelian D, Hodge JW.
Exploitation of differential homeostatic proliferation of T-cell subsets following chemotherapy to enhance the efficacy of vaccine-mediated antitumor responses.
Cancer Immunol Immunother. [Epub ahead of print], 2011.
34)  Farsaci B, Sabzevari H, Higgins JP, Di Bari MG, Takai S, Schlom J, Hodge JW.
Effect of a small molecule BCL-2 inhibitor on immune function and use with a recombinant vaccine.
Int J Cancer. 127: 1603-13, 2010.
35)  Boehm AL, Higgins J, Franzusoff A, Schlom J, Hodge JW.
Concurrent vaccination with two distinct vaccine platforms targeting the same antigen generates phenotypically and functionally distinct T-cell populations.
Cancer Immunol. Immunother. 59: 397-408, 2010.
36)  Rotow J, Gameiro S, Madan R, Gulley J, Schlom J, Hodge J.
Vaccines as monotherapy and in combination for prostate cancer.
Clin Transl Sci. 3: 116-122, 2010.
37)  Ardiani A, Higgins JP, Hodge JW.
Vaccines based on whole recombinant Saccharomyces cerevisiae cells.
FEMS Yeast Res. 10: 1060-9, 2010.
38)  Boehm A, Hodge J.
The B7-1 costimulatory molecule. In: Encyclopedia of Cancer Therapeutic Targets.
Springer; 2012. In Press. [Book Chapter]
39)  Higgins JP, Bernstein MB, Hodge JW.
Enhancing immune responses to tumor-associated antigens.
Cancer Biol. Ther. 8, 2009.
40)  Gulley JL, Arlen PM, Madan RA, Tsang KY, Pazdur MP, Skarupa L, Jones JL, Poole DJ, Higgins JP, Hodge JW, Cereda V, Vergati M, Steinberg SM, Halabi S, Jones E, Chen C, Parnes H, Wright JJ, Dahut WL, Schlom J.
Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer.
Cancer Immunol. Immunother. 59: 663-74, 2010.
41)  Madan RA, Arlen PM, Mohebtash M, Hodge JW, Gulley JL.
Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer.
Expert Opin Investig Drugs. 18: 1001-11, 2009.
42)  Gulley J, Arlen P, Hodge J, Schlom J.
Hong W, eds.
Vaccines and immunostimulants. In: Holland-Frei Cancer Medicine, 8th edition.
Shelton, CT: People's Medical Publishing House US; 2010. p. 725-736 [Book Chapter]
43)  Hodge JW, Higgins J, Schlom J.
Harnessing the unique local immunostimulatory properties of modified vaccinia Ankara (MVA) virus to generate superior tumor-specific immune responses and antitumor activity in a diversified prime and boost vaccine regimen.
Vaccine. 27: 4475-82, 2009.
44)  Ferrara TA, Hodge JW, Gulley JL.
Combining radiation and immunotherapy for synergistic antitumor therapy.
Curr. Opin. Mol. Ther. 11: 37-42, 2009.
45)  Kamrava M, Bernstein MB, Camphausen K, Hodge JW.
Combining radiation, immunotherapy, and antiangiogenesis agents in the management of cancer: the Three Musketeers or just another quixotic combination?.
Mol Biosyst. 5: 1262-70, 2009.
46)  Hodge JW, Guha C, Neefjes J, Gulley JL.
Synergizing radiation therapy and immunotherapy for curing incurable cancers. Opportunities and challenges.
Oncology (Williston Park, N.Y.). 22: 1064-70; discussion 1075, 1080-1, 1084, 2008.
47)  Bernstein MB, Chakraborty M, Wansley EK, Guo Z, Franzusoff A, Mostböck S, Sabzevari H, Schlom J, Hodge JW.
Recombinant Saccharomyces cerevisiae (yeast-CEA) as a potent activator of murine dendritic cells.
Vaccine. 26: 509-21, 2008.
48)  Wansley EK, Chakraborty M, Hance KW, Bernstein MB, Boehm AL, Guo Z, Quick D, Franzusoff A, Greiner JW, Schlom J, Hodge JW.
Vaccination with a recombinant saccharomyces cerevisiae expressing a tumor antigen breaks immune tolerance and elicits therapeutic antitumor responses.
Clin. Cancer Res. 14: 4316-25, 2008.
49)  Chakraborty M, Wansley EK, Carrasquillo JA, Yu S, Paik CH, Camphausen K, Becker MD, Goeckeler WF, Schlom J, Hodge JW.
The use of chelated radionuclide (samarium-153-ethylenediaminetetramethylenephosphonate) to modulate phenotype of tumor cells and enhance T cell-mediated killing.
Clin. Cancer Res. 14: 4241-9, 2008.
50)  Garnett CT, Schlom J, Hodge JW.
Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement.
Clin. Cancer Res. 14: 3536-44, 2008.
51)  Gulley JL, Arlen PM, Tsang K, Yokokawa J, Palena C, Poole DJ, Remondo C, Cereda V, Jones JL, Pazdur MP, Higgins JP, Hodge JW, Steinberg SM, Kotz H, Dahut WL, Schlom J.
Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma.
Clin. Cancer Res. 14: 3060-9, 2008.
52)  Chakraborty M, Gelbard A, Carrasquillo JA, Yu S, Mamede M, Paik CH, Camphausen K, Schlom J, Hodge JW.
Use of radiolabeled monoclonal antibody to enhance vaccine-mediated antitumor effects.
Cancer Immunol. Immunother. 57: 1173-83, 2008.
53)  Hodge JW.
Culture change from the top down.
Provider (Washington, D.C.). 33: 33-5, 2007.
54)  Arlen PM, Gulley JL, Madan RA, Hodge JW, Schlom J.
Preclinical and clinical studies of recombinant poxvirus vaccines for carcinoma therapy.
Crit. Rev. Immunol. 27: 451-62, 2007.
55)  Sharp HJ, Wansley EK, Garnett CT, Chakraborty M, Camphausen K, Schlom J, Hodge JW.
Synergistic antitumor activity of immune strategies combined with radiation.
Front. Biosci. 12: 4900-10, 2007.
56)  Kudo-Saito C, Garnett CT, Wansley EK, Schlom J, Hodge JW.
Intratumoral delivery of vector mediated IL-2 in combination with vaccine results in enhanced T cell avidity and anti-tumor activity.
Cancer Immunol Immunother. 2007.
57)  Kudo-Saito C, Wansley EK, Gruys ME, Wiltrout R, Schlom J, Hodge JW.
Combination therapy of an orthotopic renal cell carcinoma model using intratumoral vector-mediated costimulation and systemic interleukin-2.
Clin. Cancer Res. 13: 1936-46, 2007.
58)  Chakraborty M, Schlom J, Hodge JW.
The combined activation of positive costimulatory signals with modulation of a negative costimulatory signal for the enhancement of vaccine-mediated T-cell responses.
Cancer Immunol. Immunother. 56: 1471-84, 2007.
59)  Arlen PM, Madan RA, Hodge JW, Schlom J, Gulley JL.
Combining vaccines with conventional therapies for cancer.
Update on Cancer Therapeutics. 2: 33-39, 2007.
60)  Hodge J, Schlom J, Abrams S.
Kufe D, Bast, Jr R, Hair W, eds.
Vaccines and Immunostimulants. In: Holland-Frei Cancer Medicine, 7th edition.
Hamilton, Ontario: BC Decker; 2006. p. 786-801 [Book Chapter]
61)  Palena C, Abrams SI, Schlom J, Hodge JW.
Cancer vaccines: preclinical studies and novel strategies.
Adv. Cancer Res. 95: 115-45, 2006.
62)  Reits EA, Hodge JW, Herberts CA, Groothuis TA, Chakraborty M, Wansley EK, Camphausen K, Luiten RM, de Ru AH, Neijssen J, Griekspoor A, Mesman E, Verreck FA, Spits H, Schlom J, van Veelen P, Neefjes JJ.
Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy.
J. Exp. Med. 203: 1259-71, 2006.
63)  Kudo-Saito C, Hodge JW, Kwak H, Kim-Schulze S, Schlom J, Kaufman HL.
4-1BB ligand enhances tumor-specific immunity of poxvirus vaccines.
Vaccine. 24: 4975-86, 2006.
64)  Gelbard A, Garnett CT, Abrams SI, Patel V, Gutkind JS, Palena C, Tsang KY, Schlom J, Hodge JW.
Combination chemotherapy and radiation of human squamous cell carcinoma of the head and neck augments CTL-mediated lysis.
Clin. Cancer Res. 12: 1897-905, 2006.
65)  Garnett CT, Greiner JW, Tsang KY, Kudo-Saito C, Grosenbach DW, Chakraborty M, Gulley JL, Arlen PM, Schlom J, Hodge JW.
TRICOM vector based cancer vaccines.
Curr. Pharm. Des. 12: 351-61, 2006.
66)  Hodge JW, Greiner JW, Tsang KY, Sabzevari H, Kudo-Saito C, Grosenbach DW, Gulley JL, Arlen PM, Marshall JL, Panicali D, Schlom J.
Costimulatory molecules as adjuvants for immunotherapy.
Front. Biosci. 11: 788-803, 2006.
67)  Palena C, Foon KA, Panicali D, Yafal AG, Chinsangaram J, Hodge JW, Schlom J, Tsang KY.
Potential approach to immunotherapy of chronic lymphocytic leukemia (CLL): enhanced immunogenicity of CLL cells via infection with vectors encoding for multiple costimulatory molecules.
Blood. 106: 3515-23, 2005.
68)  Hodge JW, Chakraborty M, Kudo-Saito C, Garnett CT, Schlom J.
Multiple costimulatory modalities enhance CTL avidity.
J. Immunol. 174: 5994-6004, 2005.
69)  Gulley JL, Arlen PM, Bastian A, Morin S, Marte J, Beetham P, Tsang KY, Yokokawa J, Hodge JW, Ménard C, Camphausen K, Coleman CN, Sullivan F, Steinberg SM, Schlom J, Dahut W.
Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer.
Clin. Cancer Res. 11: 3353-62, 2005.
70)  Kudo-Saito C, Schlom J, Hodge JW.
Induction of an antigen cascade by diversified subcutaneous/intratumoral vaccination is associated with antitumor responses.
Clin. Cancer Res. 11: 2416-26, 2005.
71)  Marshall JL, Gulley JL, Arlen PM, Beetham PK, Tsang KY, Slack R, Hodge JW, Doren S, Grosenbach DW, Hwang J, Fox E, Odogwu L, Park S, Panicali D, Schlom J.
Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas.
J. Clin. Oncol. 23: 720-31, 2005.
72)  Yang S, Hodge JW, Grosenbach DW, Schlom J.
Vaccines with enhanced costimulation maintain high avidity memory CTL.
J. Immunol. 175: 3715-23, 2005.
73)  Kudo-Saito C, Schlom J, Camphausen K, Coleman CN, Hodge JW.
The requirement of multimodal therapy (vaccine, local tumor radiation, and reduction of suppressor cells) to eliminate established tumors.
Clin Cancer Res. 11: 4533-44, 2005.
74)  Garnett CT, Palena C, Chakraborty M, Chakarborty M, Tsang KY, Schlom J, Hodge JW.
Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes.
Cancer Res. 64: 7985-94, 2004.
75)  Schlom J, Palena C, Greiner JW, Tsang KY, Grosenbach DW, Sabzevari H, Gulley JL, Arlen PM, Kass E, Hodge JW.
Combinatorial vaccine strategies and the use of molecular arrays to characterize T-cell activation.
Dev Biol (Basel). 116: 27-47, 2004.
76)  Chakraborty M, Abrams SI, Coleman CN, Camphausen K, Schlom J, Hodge JW.
External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing.
Cancer Res. 64: 4328-37, 2004.
77)  Zeytin HE, Patel AC, Rogers CJ, Canter D, Hursting SD, Schlom J, Greiner JW.
Combination of a poxvirus-based vaccine with a cyclooxygenase-2 inhibitor (celecoxib) elicits antitumor immunity and long-term survival in CEA.Tg/MIN mice.
Cancer Res. 64: 3668-78, 2004.
78)  Slavin-Chiorini DC, Catalfamo M, Kudo-Saito C, Hodge JW, Schlom J, Sabzevari H.
Amplification of the lytic potential of effector/memory CD8+ cells by vector-based enhancement of ICAM-1 (CD54) in target cells: implications for intratumoral vaccine therapy.
Cancer Gene Ther. 11: 665-80, 2004.
79)  Kudo-Saito C, Schlom J, Hodge JW.
Intratumoral vaccination and diversified subcutaneous/ intratumoral vaccination with recombinant poxviruses encoding a tumor antigen and multiple costimulatory molecules.
Clin. Cancer Res. 10: 1090-9, 2004.
80)  Hodge JW, Poole DJ, Aarts WM, Gómez Yafal A, Gritz L, Schlom J.
Modified vaccinia virus ankara recombinants are as potent as vaccinia recombinants in diversified prime and boost vaccine regimens to elicit therapeutic antitumor responses.
Cancer Res. 63: 7942-9, 2003.
81)  Grosenbach DW, Schlom J, Gritz L, Gómez Yafal A, Hodge JW.
A recombinant vector expressing transgenes for four T-cell costimulatory molecules (OX40L, B7-1, ICAM-1, LFA-3) induces sustained CD4+ and CD8+ T-cell activation, protection from apoptosis, and enhanced cytokine production.
Cell. Immunol. 222: 45-57, 2003.
82)  Chakraborty M, Abrams SI, Camphausen K, Liu K, Scott T, Coleman CN, Hodge JW.
Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy.
J. Immunol. 170: 6338-47, 2003.
83)  Schlom J, Sabzevari H, Grosenbach DW, Hodge JW.
A triad of costimulatory molecules synergize to amplify T-cell activation in both vector-based and vector-infected dendritic cell vaccines.
Artificial cells, blood substitutes, and immobilization biotechnology. 31: 193-228, 2003.
84)  Hodge JW, Grosenbach DW, Aarts WM, Poole DJ, Schlom J.
Vaccine therapy of established tumors in the absence of autoimmunity.
Clin. Cancer Res. 9: 1837-49, 2003.
85)  Oh S, Hodge JW, Ahlers JD, Burke DS, Schlom J, Berzofsky JA.
Selective induction of high avidity CTL by altering the balance of signals from APC.
J. Immunol. 170: 2523-30, 2003.
86)  Hodge JW, Tsang KY, Poole DJ, Schlom J.
General keynote: vaccine strategies for the therapy of ovarian cancer.
Gynecol. Oncol. 88: S97-104; discussion S110-3, 2003.
87)  Hodge JW, Grosenbach DW, Schlom J.
Vector-based delivery of tumor-associated antigens and T-cell co-stimulatory molecules in the induction of immune responses and anti-tumor immunity.
Cancer Detect. Prev. 26: 275-91, 2002.
88)  Aarts WM, Schlom J, Hodge JW.
Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity.
Cancer Res. 62: 5770-7, 2002.
89)  Schmitz J, Reali E, Hodge JW, Patel A, Davis G, Schlom J, Greiner JW.
Identification of an interferon-gamma-inducible carcinoembryonic antigen (CEA) CD8(+) T-cell epitope, which mediates tumor killing in CEA transgenic mice.
Cancer Res. 62: 5058-64, 2002.
90)  Shankar P, Schlom J, Hodge JW.
Enhanced activation of rhesus T cells by vectors encoding a triad of costimulatory molecules (B7-1, ICAM-1, LFA-3).
Vaccine. 20: 744-55, 2001.
91)  Rad AN, Schlom J, Hodge JW.
Vector-driven hyperexpression of a triad of costimulatory molecules confers enhanced T-cell stimulatory capacity to DC precursors.
Crit. Rev. Oncol. Hematol. 39: 43-57, 2001.
92)  Grosenbach DW, Barrientos JC, Schlom J, Hodge JW.
Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects.
Cancer Res. 61: 4497-505, 2001.
93)  Hodge JW, Grosenbach DW, Rad AN, Giuliano M, Sabzevari H, Schlom J.
Enhancing the potency of peptide-pulsed antigen presenting cells by vector-driven hyperexpression of a triad of costimulatory molecules.
Vaccine. 19: 3552-67, 2001.
94)  Baker EJ, Ichiki AT, Hodge JW, Sugantharaj D, Bamberger EG, Lozzio CB.
PMA-treated K-562 leukemia cells mediate a TH2-specific expansion of CD4+ T cells in vitro.
Leuk. Res. 24: 1049-57, 2000.
95)  Hodge JW, Schlom J.
Costimulatory molecules in vaccine design.
Ernst Schering Res. Found. Workshop. 23-52, 2000.
96)  Hodge JW, Rad AN, Grosenbach DW, Sabzevari H, Yafal AG, Gritz L, Schlom J.
Enhanced activation of T cells by dendritic cells engineered to hyperexpress a triad of costimulatory molecules.
J. Natl. Cancer Inst. 92: 1228-39, 2000.
97)  Freund YR, Mirsalis JC, Fairchild DG, Brune J, Hokama LA, Schindler-Horvat J, Tomaszewski JE, Hodge JW, Schlom J, Kantor JA, Tyson CA, Donohue SJ.
Vaccination with a recombinant vaccinia vaccine containing the B7-1 co-stimulatory molecule causes no significant toxicity and enhances T cell-mediated cytotoxicity.
Int. J. Cancer. 85: 508-17, 2000.
98)  Schlom J, Tsang KY, Kantor JA, Abrams SI, Zaremba S, Greiner J, Hodge JW.
Strategies in the development of recombinant vaccines for colon cancer.
Semin. Oncol. 26: 672-82, 1999.
99)  Hodge JW, Sabzevari H, Yafal AG, Gritz L, Lorenz MG, Schlom J.
A triad of costimulatory molecules synergize to amplify T-cell activation.
Cancer Res. 59: 5800-7, 1999.
100)  Schlom J, Hodge JW.
The diversity of T-cell co-stimulation in the induction of antitumor immunity.
Immunol. Rev. 170: 73-84, 1999.
101)  Hodge JW, Schlom J.
Comparative studies of a retrovirus versus a poxvirus vector in whole tumor-cell vaccines.
Cancer Res. 59: 5106-11, 1999.
102)  Lorenz MG, Kantor JA, Schlom J, Hodge JW.
Anti-tumor immunity elicited by a recombinant vaccinia virus expressing CD70 (CD27L).
Hum. Gene Ther. 10: 1095-103, 1999.
103)  Lorenz MG, Kantor JA, Schlom J, Hodge JW.
Induction of anti-tumor immunity elicited by tumor cells expressing a murine LFA-3 analog via a recombinant vaccinia virus.
Hum. Gene Ther. 10: 623-31, 1999.
104)  Kalus RM, Kantor JA, Gritz L, Gómez Yafal A, Mazzara GP, Schlom J, Hodge JW.
The use of combination vaccinia vaccines and dual-gene vaccinia vaccines to enhance antigen-specific T-cell immunity via T-cell costimulation.
Vaccine. 17: 893-903, 1999.
105)  Ichiki AT, Langenberg M, Baker EJ, Hodge JW, Bamberger EG, Gerard DA, Lozzio CB.
Differential regulation of interleukin-1alpha and interleukin-1beta in K-562 cells.
J. Interferon Cytokine Res. 18: 1045-50, 1998.
106)  Schlom J, Tsang KY, Kantor JA, Abrams SI, Zaremba S, Greiner J, Hodge JW.
Cancer vaccine development.
Expert opinion on investigational drugs. 7: 1439-52, 1998.
107)  Uzendoski K, Kantor JA, Abrams SI, Schlom J, Hodge JW.
Construction and characterization of a recombinant vaccinia virus expressing murine intercellular adhesion molecule-1: induction and potentiation of antitumor responses.
Hum. Gene Ther. 8: 851-60, 1997.
108)  Hodge JW, McLaughlin JP, Kantor JA, Schlom J.
Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses.
Vaccine. 15: 759-68, 1997.
109)  Abrams SI, Hodge JW, McLaughlin JP, Steinberg SM, Kantor JA, Schlom J.
Adoptive immunotherapy as an in vivo model to explore antitumor mechanisms induced by a recombinant anticancer vaccine.
J. Immunother. 20: 48-59, 1997.
110)  Akagi J, Hodge JW, McLaughlin JP, Gritz L, Mazzara G, Kufe D, Schlom J, Kantor JA.
Therapeutic antitumor response after immunization with an admixture of recombinant vaccinia viruses expressing a modified MUC1 gene and the murine T-cell costimulatory molecule B7.
J. Immunother. 20: 38-47, 1997.
111)  Hodge JW.
Carcinoembryonic antigen as a target for cancer vaccines.
Cancer Immunol. Immunother. 43: 127-34, 1996.
112)  Hodge JW, Schlom J, Donohue SJ, Tomaszewski JE, Wheeler CW, Levine BS, Gritz L, Panicali D, Kantor JA.
A recombinant vaccinia virus expressing human prostate-specific antigen (PSA): safety and immunogenicity in a non-human primate.
Int. J. Cancer. 63: 231-7, 1995.
113)  Hodge JW, McLaughlin JP, Abrams SI, Shupert WL, Schlom J, Kantor JA.
Admixture of a recombinant vaccinia virus containing the gene for the costimulatory molecule B7 and a recombinant vaccinia virus containing a tumor-associated antigen gene results in enhanced specific T-cell responses and antitumor immunity.
Cancer Res. 55: 3598-603, 1995.
114)  Hodge JW, Abrams S, Schlom J, Kantor JA.
Induction of antitumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 costimulatory molecules.
Cancer Res. 54: 5552-5, 1994.
115)  Wust CJ, Hodge JW, Ichiki AT, Lozzio CB.
Cell death in the human leukemia cell line, K-562, induced by antiserum and monoclonal antibodies.
Leuk. Res. 15: 497-506, 1991.
116)  Hodge JW, Wust CJ, Ichiki AT, Lozzio CB.
Antibodies to specific cell surface antigens of a human leukemia cell line, K-562, transduce negative growth signals.
Ann. N. Y. Acad. Sci. 628: 165-8, 1991.
Click Here to View Collapsed Bibliography.

This page was last updated on 4/17/2014.